New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
16:16 EDTGHDXGenomic Health sees FY13 EPS ex-items 48c-68c, consensus 28c
Sees FY13 revenue $258M-$266M, consensus $262.4M. The company said, "In 2013, we plan to continue to invest in near-term opportunities to expand our global breast and colon cancer businesses in order to drive top-line revenue growth, and in our prostate cancer launch to build long-term value, and expect losses in the first and second quarters." Sees FY13 GAAP EPS (12c)-8c and non-GAAP basic EPS, excluding stock compensation expense, 48c-68c.
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
07:55 EDTGHDXGenomic Health remains a top pick, says Cowen
Cowen noted Genomic Health reported in-line Q4 results, but said with the recent price depreciation the shares are increasingly attractive and remain a top pick. Cowen reiterated its Outperform rating and $40 price target on Genomic Health.
February 10, 2016
16:18 EDTGHDXGenomic Health sees FY16 EPS (55c)-(37c), consensus (13c)
Sees FY16 revenue $320M-$335M, consensus $328.76M. Sees FY16 Oncotype DX tests delivered of 117,500 to 121,000, representing growth of between 10%-13% compared to 2015.
16:17 EDTGHDXGenomic Health reports Q4 EPS (10c), consensus (9c)
Reports Q4 revenue $74.5M, consensus $74.87M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use